Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cantor Fitzgerald

2Q Canada Recreational Cannabis Market Analysis: +21 YoY Growth Outperforming The U.S.

In a recent analyst note, Cantor Fitzgerald's Pablo Zuanic gave an overview of the Canadian recreational cannabis market in the second quarter of 2022, according to data collected by Hifyre, a leading in-shop and online digital toolset for cannabis dispensaries.

Cantor's Top Picks: Could Q2 Earnings Provide A Spark For These Cannabis Multi-State Operators?

Cantor's Top Picks: Could Q2 Earnings Provide A Spark For These Cannabis Multi-State Operators?

Multi-State Operators (MSO) traded higher on Tuesday after Cantor Fitzgerald categorized four companies as "top picks." In a recent industry report, Pablo Zuanic analyzed the context of MSOs and offered insight on trends driving financial value. Although MSOs ETF fell 25% in June and 49% over the last three months (vs.

Read Why Cantor Upgraded Aurora Cannabis Stock

Read Why Cantor Upgraded Aurora Cannabis Stock

Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Cantor Fitzgerald Maintains Neutral Rating for High Tide: Here's What You Need To Know

Cantor Fitzgerald has decided to maintain its Neutral rating of High Tide (NASDAQ:HITI) and lower its price target from $7.00 to $4.45. Shares of High Tide are trading down 1.7% over the last 24 hours, at $2.02 per share. A move to $4.45 would account for a 120.82% increase from…

High Tide: 'Continued Progress, But More Operational Leverage Needed,' Analyst Says

The Analyst Pablo Zuanic from Cantor Fitzgerald remained ‘Neutral' on High Tide Inc. (NASDAQ: HITI) and lowered the stock 12-month price target to C$4.45 from C$7 “given overall sectoral derating.”

HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response (CR) rate. From a safety perspective, eight of 117 patients developed Guillain-Barré syndrome…

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

After A Challenging March Quarter Canopy Growth Projects Positive EBITDA By FY 2024

After A Challenging March Quarter Canopy Growth Projects Positive EBITDA By FY 2024

Pablo Zuanic from Cantor Fitzgerald kept a rating of “Neutral” for the stocks of Canopy Growth Corp. (TSE: WEED) (NASDAQ: CGC) and lowered his 12-month price target to C$6.75 from C$7.75 due to the sectoral derating and red

AYR Wellness: Management Expects 'Significant Sales' And 'EBITDA Ramp' In 2022

AYR Wellness: Management Expects 'Significant Sales' And 'EBITDA Ramp' In 2022

The Analyst Pablo Zuanic from Cantor Fitzgerald kept a rating of "Neutral" on Ayr Wellness Inc. (OTC: AYRWF) stocks and lowered its 12-month price target to $6.75 from $13.30, due to reduced estimates and overall sectoral derating.

Cresco Lab's 1Q Results After Conference Call, Analyst Opines

Cresco Lab's 1Q Results After Conference Call, Analyst Opines

The Analyst Following Cresco Labs’ (OTC: CRLBF) (CSE:CL) conference call, Pablo Zuanic, from Cantor Fitzgerald kept an "Overweight" rating and maintained a 12-month price target of $19.

Columbia Care: Challenging 1Q, Stock Is Now Tied to Cresco Deal Analyst Says

Columbia Care: Challenging 1Q, Stock Is Now Tied to Cresco Deal Analyst Says

The Analyst Pablo Zuanic, from Cantor Fitzgerald, rated Columbia Care Inc. (OTC: CCHWF) as Overweight with a price target of $5.10.

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

Cantor Fitzgerald Lowers Price Target On Trulieve Post Earnings, Here's Why

Cantor Fitzgerald Lowers Price Target On Trulieve Post Earnings, Here's Why

Trulieve Cannabis Corp.

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

Analyst On Cresco's Deal With Columbia Care And Earnings Results For Q4 2021

The Analyst: Pablo Zuanic, from Cantor Fitzgerald, rated Cresco Labs, Inc. (OTC: CRLBF) as Overweight with a price target of $19.00.

This Satellite Semiconductor Firm Looks To Go Public Via SPAC Merger With Endurance

Bloomberg reports that satellite semiconductor provider SatixFy Communications Ltd agreed to go public via a special purpose acquisition company (SPAC) merger. SatixFy's deal with Endurance Acquisition Corp (NASDAQ:EDNC) will give the combined company a pro forma implied equity value of about $813 million. Israel-based SatixFy is a fabless semiconductor company providing products based on its own…

Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy'

Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating.

Brief Thoughts Ahead Of 4Q For Curaleaf Holdings: New Jersey Could Be Next Main Catalyst

The Analyst Pablo Zuanic, from Cantor Fitzgerald, kept Curaleaf among the firm’s top picks in the MSO group, with an Overweight rating and a price target at US$16.50. The Thesis

Get all your
news in one place.

100’s of premium titles.
One news app.

Green Thumb Industries Among Top Cannabis MSO Stocks Ahead Of Earnings Season, Analyst Tells Us Why

As earnings season approaches, Cantor Fitzgerald analyst Pablo Zuanic discussed his expectations. One of his top stock picks, Green Thumb Industries Inc.

Analyst: Dissecting Marijuana Sales Growth And Cannabis Dispensary Performance in Florida

In a recent analyst note, Pablo Zuanic from Cantor Fitzgerald takes a close look at Florida's operators regarding store trends and total sales growth. The Florida medical marijuana market has continued to slow in the first quarter of 2022, after mid-teens sequential growth earlier in 2021.

Cannabis Analyst Advises Not To Buy WeedMaps Shares Until March

Cantor Fitzgerald has issued a new report on cannabis tech platform WeedMaps (NASDAQ: MAPS), also known as WM Technology Inc.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

260,361 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play